ABVC BioPharma, Inc. filed a Form S-8 registration statement with the U.S. Securities and Exchange Commission on November 16, 2026, to register 6,610,923 shares of common stock under its newly approved 2026 Equity Incentive Plan.

Key Highlights

  • Total shares registered: 6,610,923 shares of common stock, par value $0.001 per share, under the 2026 Equity Incentive Plan.
  • Three-part share pool: The registered shares consist of 1,169,201 previously reserved shares, 4,046,493 shares representing 15% of shares outstanding as of October 28, 2026, and 1,395,229 shares anticipated under an evergreen provision on January 1, 2027.
  • Plan approval date: Stockholders approved the 2026 Equity Incentive Plan at a special meeting on October 28, 2026.
  • Shares issued and outstanding: 26,976,625 shares were issued and outstanding as of October 28, 2026; as of the filing date, that figure was reported as 27,062,910 shares.
  • Evergreen estimate basis: The 1,395,229 evergreen shares were estimated assuming 27,904,594 shares of common stock issued and outstanding as of December 31, 2026, rounded down to the nearest whole share, solely for registration purposes.
  • Capital structure: The company's authorized capital consists of 100,000,000 shares of common stock and 20,000,000 shares of preferred stock, each at $0.001 par value; no preferred stock is currently outstanding, according to the filing.

ABVC BioPharma Registers 6.6 Million Shares Under 2026 Incentive Plan

ABVC BioPharma, Inc. (NASDAQ:ABVC), a Nevada-incorporated biopharmaceutical company headquartered in Fremont, California, filed a Form S-8 registration statement on November 16, 2026, to register shares of common stock issuable under its 2026 Equity Incentive Plan. According to the filing, the registration covers a total of 6,610,923 shares, par value $0.001 per share.

The filing discloses that the share pool is composed of three components. The first is 1,169,201 shares already set aside. The second is 4,046,493 shares, which the filing describes as "representing 15% of the 26,976,625 shares of common stock issued and outstanding as of October 28, 2026, the date the Plan was approved by the stockholders at the special meeting, rounded down to the nearest whole share." The third component is 1,395,229 shares anticipated to become available on January 1, 2027 under the plan's evergreen provision. The filing notes these evergreen shares were "estimated solely for registration purposes" by assuming 27,904,594 shares outstanding as of December 31, 2026.

As of the filing date, the company reported 27,062,910 shares of common stock issued and outstanding. No preferred stock is outstanding, according to the filing. The company's authorized capital consists of 100,000,000 shares of common stock and 20,000,000 shares of preferred stock. The filing was signed by Dr. Uttam Patil, identified as Chief Executive Officer, and legal counsel is listed as Hunter Taubman Fischer and Li LLC of New York.

What Was Disclosed

ABVC BioPharma filed a Form S-8 on November 16, 2026, registering 6,610,923 shares of common stock under its stockholder-approved 2026 Equity Incentive Plan, including an evergreen component estimated for January 1, 2027 issuance.